- |||||||||| para-toluenesulfonamide (PTS100) / Gongwin Biopharm
Trial completion date, Trial primary completion date: OASES: A Study of PTS100 in Primary HCC Patients (clinicaltrials.gov) - Mar 29, 2022
P2, N=33, Recruiting,
PTS alone and PTS combined with cisplatin may be antitumor agents for canine melanoma treatment. Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Dec 2024
- |||||||||| Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] FIRST INTERIM RESULTS OF THE RUSSIAN PROSPECTIVE STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI (READIT) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE () - May 13, 2021 - Abstract #EHA2021EHA_1317;
Aims To provide the first interim results of the «Study of REduction And DIscontinuation Treatment of TKI (READIT)» (NCT 04578847): evaluation of the response rates and first data of imatinib (IM) plasma blood concentrations after dose reduction...The TKI dose reduction phase consists of two 6 mo steps: 1st step (300 mg for IM, 400 mg for nilotinib (NIL), 50 mg for dasatinib (DAS) and 300 mg for bosutinib (BOS)) and 2nd step (25 mg for DAS and 200 mg for IM, NIL and BOS) of TKI dose reduction...At baseline 46 (66%) pts received IM (39 pts-400 mg, 3 pts–300 mg, 4 pts–200 mg) and 24 (34%) pts - second-generation (2G) TKI: NIL - 13 pts (6 pts-800-600 mg, 6 pts-400 mg, 1 pt–200 mg), DAS- 6 pts (4 pts-100-70 mg, 2 pts–50 mg), BOS- 5 pts (1 pt–500 mg, 2 pts–300 mg, 2 pts–200 mg)...The results will be updated within a longer follow-up in order to evaluate the impact of de-escalation phase on TFR rates. The role of different TKI concentrations will be studied.
- |||||||||| para-toluenesulfonamide (PTS100) / Gongwin Biopharm
Journal: Cysteine Prevents the Development of Experimental Diabetes Induced by Zinc-Binding Substances. (Pubmed Central) - Feb 4, 2021
Injection of cysteine few minutes after dithizone and formation of zinc-dithizone complex was followed by displacement of dithizone from the complex and prevented the development of diabetes in most animals. The most plausible mechanism of preventive effect of cysteine is the formation of 2:1 zinc-cysteine complex in β cells with possible fixation of Zn atom between sulfur atoms from SH groups of two cysteine molecules.
- |||||||||| para-toluenesulfonamide (PTS100) / Gongwin Biopharm
Trial completion date, Trial primary completion date: OASES: A Study of PTS100 in Primary HCC Patients (clinicaltrials.gov) - Feb 5, 2020
P2, N=33, Recruiting,
The most plausible mechanism of preventive effect of cysteine is the formation of 2:1 zinc-cysteine complex in β cells with possible fixation of Zn atom between sulfur atoms from SH groups of two cysteine molecules. Trial completion date: Apr 2022 --> Dec 2023 | Trial primary completion date: Jul 2019 --> Dec 2021
- |||||||||| para-toluenesulfonamide (PTS100) / Gongwin Biopharm
Enrollment open, Trial initiation date: OASES: A Study of PTS100 in Primary HCC Patients (clinicaltrials.gov) - Aug 2, 2018
P2, N=33, Recruiting,
Trial completion date: Apr 2022 --> Dec 2023 | Trial primary completion date: Jul 2019 --> Dec 2021 Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Jun 2018
|
